Clinical Parkinsonism Related Disorders最新文献

{"title":"Long-term real-world effectiveness of carbidopa/levodopa enteral suspension after 36 months of treatment initiation in advanced Parkinson's disease in the US: final results from the PROviDE study","authors":"Rajesh Pahwa,&nbsp;Stuart H. Isaacson,&nbsp;David Cella,&nbsp;Sandeep Thakkar,&nbsp;Prasanna L. Kandukuri,&nbsp;Connie H. Yan,&nbsp;Pavnit Kukreja,&nbsp;Irene Pan,&nbsp;Jae Lee,&nbsp;Jason Aldred","doi":"10.1016/j.prdoa.2026.100488","DOIUrl":"10.1016/j.prdoa.2026.100488","url":null,"abstract":"<div><div><strong>Introduction:</strong> Clinical trials and observational studies have demonstrated that carbidopa/levodopa enteral suspension (CLES) significantly improves advanced Parkinson's disease (aPD) symptoms. This study examined the real-world, long-term impact of CLES on patient-reported outcomes (PROs) in people with aPD.</div><div><strong>Methods:</strong> Pursuing Real-World Outcomes via Duopa Ecosystem (PROviDE) was a 36-month prospective, observational study evaluating the effectiveness of CLES in patients with aPD in the US. PROs were collected at baseline, 3 months, and every 6 months after CLES initiation and included OFF-time, Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9), and Parkinson's Disease Questionnaire-8 (PDQ-8) assessing PD-related quality of life (QoL). Longitudinal treatment effects were evaluated using mixed-effect models.</div><div><strong>Results:</strong> Of 104 patients, 47 (45.2%) provided 36 months of data and were evaluated in the final mixed-model analysis. Patients mean standard deviation (SD) age was 67.0 (8.7) years with a mean (SD) PD diagnosis of 11.0 (6.2) years. Compared with baseline, CLES resulted in statistically significant and clinically meaningful improvements in hours of OFF-time as early as month 3 (mean: −2.7 h/day, <em>p</em> &lt; .0001) and sustained at month 36 (−1.7 h/day, <em>p</em> = .004). Improvements were also observed in treatment effectiveness (≥19 points, all p &lt; .0001), global satisfaction with treatment and convenience of therapy (≥10 points each; all <em>p</em> &lt; .001) over 36 months. A statistically significant improvement in PDQ-8 was observed as early as month 3 (−4.1, <em>p</em> = .001) with no worsening over time.</div><div><strong>Conclusion:</strong> Long-term treatment with CLES provides significant and clinically meaningful reduction in OFF-time, patient's treatment satisfaction, and maintained QoL in the real-world setting.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100488"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148642651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nocturnal heart rate variability in Parkinson's disease: associations with autonomic dysfunction, cognitive function, and mood symptoms","authors":"Cindy Li,&nbsp;Lina Kleinschmidt,&nbsp;Yatharth Sunkara,&nbsp;Ethan George,&nbsp;Steven M. Pogwizd,&nbsp;Adeel A. Memon,&nbsp;Amy W. Amara","doi":"10.1016/j.prdoa.2026.100483","DOIUrl":"10.1016/j.prdoa.2026.100483","url":null,"abstract":"<div><h3>Introduction</h3><div>Heart Rate Variability (HRV) analysis reflects beat-to-beat fluctuations in RR intervals, serving as a method to non-invasively monitor sympatho-vagal balance during sleep. The primary aim of this study is to investigate nocturnal HRV in Parkinson's Disease (PD). In addition, we explore its association with various non-motor symptoms.</div></div><div><h3>Methods</h3><div>In 36 participants with PD and 20 healthy controls (HC), frequency-domain HRV analysis of polysomnography-derived electrocardiogram data was conducted to derive low-frequency power (LF), high-frequency power (HF), and LF/HF ratio in NREM and REM sleep. In PD subjects, Spearman correlations were determined between HRV variables and the MDS-UPDRS sub-scores for autonomic symptoms (1.10–1.12) and mood (1.3, 1.4), the Pittsburgh Sleep Quality Index (PSQI), the Beck Depression Inventory (BDI), and a comprehensive neurocognitive battery.</div></div><div><h3>Results</h3><div>Individuals with PD demonstrated lower LF (NREM <em>p</em> = 0.037, REM <em>p</em> = 0.007), lower LF/HF (NREM <em>p</em> = 0.046, REM <em>p</em> = 0.0106), and higher HF (NREM <em>p</em> = 0.037, REM <em>p</em> = 0.008) compared to HC subjects. In PD subjects, executive function and processing speed were negatively correlated with LF and LF/HF (p = 0.03; <em>p</em> = 0.033) and positively correlated with HF (<em>p</em> = 0.029; p = 0.033) during NREM. Greater severity of lightheadedness and urinary problems correlated with worse performance in multiple cognitive domains and higher BDI scores.</div></div><div><h3>Conclusion</h3><div>Our findings offer novel insight into the association between HRV and non-motor symptoms in PD. Individuals with PD have reduced sympathetic influence on HRV during sleep compared to HC. However, stronger parasympathetic influence correlates with better cognitive performance. Furthermore, subjective autonomic symptoms are correlated with poorer cognition and mood.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100483"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148737400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in sleep disturbances and quality of life associated with Istradefylline in patients with Parkinson's disease: an exploratory polysomnographic study","authors":"Noriyuki Miyaue,&nbsp;Hayato Yabe","doi":"10.1016/j.prdoa.2026.100512","DOIUrl":"10.1016/j.prdoa.2026.100512","url":null,"abstract":"<div><h3>Background</h3><div>Sleep disturbances are common non-motor symptoms in Parkinson's disease (PD) and substantially impair quality of life (QOL). Although istradefylline, an adenosine A2A receptor antagonist, is widely used to improve motor fluctuations, its effects on subjective sleep complaints and objective sleep architecture remain unclear.</div></div><div><h3>Methods</h3><div>In this exploratory, single-center, open-label study, we evaluated changes in subjective sleep quality and polysomnographic findings following 12 weeks of istradefylline treatment in patients with PD. Nine patients underwent clinical assessments and overnight polysomnography at baseline and 12 weeks after initiating istradefylline (20 mg/day). Sleep quality, QOL, fatigue, and motor symptoms were assessed using validated clinical scales.</div></div><div><h3>Results</h3><div>Following istradefylline initiation, improvements were observed in Parkinson's Disease Sleep Scale-2 (PDSS-2), Parkinson's Disease Questionnaire-39 summary index (PDQ-39 SI), Parkinson Fatigue Scale, and Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV scores. Changes in PDSS-2 scores were significantly correlated with changes in PDQ-39 SI (ρ = 0.76, <em>p</em> = 0.017), although both measures were subjective and obtained at the same assessment. Regarding objective sleep measures, most polysomnographic parameters did not significantly change; rapid eye movement (REM) sleep percentage increased numerically, but the change was not statistically significant (<em>p</em> = 0.058).</div></div><div><h3>Conclusions</h3><div>In this small uncontrolled study, initiation of istradefylline was associated with improvements in subjective sleep quality, fatigue, and QOL, whereas objective polysomnographic parameters showed limited changes. These findings are exploratory and hypothesis-generating and require confirmation in larger controlled studies.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100512"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149199253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Motor and non-motor outcomes post rehabilitation for persons with freezing of gait and Parkinson's disease: A systematic review and Meta-analysis","authors":"Jessica E. Bath,&nbsp;Diane D. Allen,&nbsp;Valerie J. Block","doi":"10.1016/j.prdoa.2026.100498","DOIUrl":"10.1016/j.prdoa.2026.100498","url":null,"abstract":"<div><h3>Introduction</h3><div>Freezing of gait (FOG), a symptom of Parkinson's disease (PD), involves dysfunction across motor, cognitive, and limbic domains. Rehabilitation for PD traditionally emphasizes motor impairments, leaving non-motor FOG contributors underexplored, which may contribute to limited understanding of mechanisms underlying FOG or optimal FOG rehabilitation. To investigate this, we quantified within-group clinical outcomes related to postural control, executive function, and limbic domains to evaluate the impacts of rehabilitation studies on multidomain FOG pathophysiology in people with PD and FOG (PD + FOG).</div></div><div><h3>Methods</h3><div>Search of PubMed and CINAHL used terms PD, FOG, rehabilitation, postural control, cognitive, and limbic outcomes. Full-text articles were assessed by two reviewers to confirm their eligibility. Eligible studies utilized &gt;1 rehabilitation intervention session, reported pre- and post-training data for ≥1 FOG-related symptom domain outcome specifically for PD + FOG. Fixed or random effect meta-analyses were conducted for each domain, resulting in summary effect sizes Cohen's d (95% confidence interval) reflecting standardized within-group changes.</div></div><div><h3>Results</h3><div>The search returned eighteen studies eligible for data extraction. Postural control results: 17 unique participant groups (<em>n</em> = 458), <em>d</em> = 0.49 (0.36, 0.62). Cognitive processing results: 8 unique participant groups (<em>n</em> = 193), d = −0.22 (−0.42, −0.02). Limbic (anxiety, depression) results: 4 unique participant groups (<em>n</em> = 55), d = −0.08 (−0.45, 0.30).</div></div><div><h3>Discussion</h3><div>Postural control and cognitive domain outcomes demonstrated significant post-intervention improvements following rehabilitation for PD + FOG. Limbic domain results showed small, nonsignificant pre-post changes. Few studies reported clinical outcome measures covering motor and non-motor domains. Further studies should assess motor and non-motor FOG-related domains and more comprehensive rehabilitation approaches for PD + FOG populations.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100498"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149003918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Pharmacological interventions for managing fatigue in parkinson’s disease: A systematic review and meta-analysis","authors":"Sarah Alageel ,&nbsp;Jane Hibberd ,&nbsp;Katherine H.O. Deane","doi":"10.1016/j.prdoa.2026.100434","DOIUrl":"10.1016/j.prdoa.2026.100434","url":null,"abstract":"<div><h3>Background</h3><div>Fatigue is a prevalent and disabling non-motor symptom in Parkinson’s disease (PD), yet evidence for effective management strategies, particularly non-pharmacological approaches, remains limited.</div></div><div><h3>Objective</h3><div>To systematically review and <em>meta</em>-analyse the efficacy of non-pharmacological interventions aimed at reducing fatigue in people with PD (PwP).</div></div><div><h3>Methods</h3><div>MEDLINE, CINAHL and AMED were searched from inception to January 2026 for randomised controlled trials (RCTs) in which fatigue was a primary outcome. Risk of bias was assessed using the Cochrane RoB2 tool. Standardised mean differences (SMDs) were pooled using random-effects models, and certainty of evidence was assessed using GRADE. The protocol was registered with PROSPERO (CRD42023394180).</div></div><div><h3>Results</h3><div>Five RCTs (n = 270 participants) met the inclusion criteria, evaluating exercise-based interventions (3 trials, n = 142) and acupuncture (2 trials, n = 128). Exercise interventions were associated with a statistically significant reduction in fatigue compared with controls (SMD =  − 1.34, 95% CI − 2.24 to − 0.44, p = 0.003), although heterogeneity was substantial (I2 = 89%). Acupuncture showed no significant effect compared with sham (SMD = 0.17, 95% CI − 0.13 to 0.51, p = 0.26), with low heterogeneity (I2 = 0%). Risk of bias was low in the acupuncture trials but rated as ‘some concerns’ for all exercise trials. GRADE assessment indicated low certainty evidence for exercise and moderate certainty evidence for acupuncture. Secondary outcomes such as quality of life and sleep were inconsistently reported and showed minimal change.</div></div><div><h3>Conclusions</h3><div>Exercise-based interventions show preliminary promise for reducing fatigue severity in PwP, but the evidence is limited by heterogeneity and methodological concerns. Acupuncture appears ineffective compared to sham. High-quality, adequately powered RCTs evaluating diverse non-pharmacological approaches, including psychological and self-management strategies, are urgently needed, using standardised PD-specific fatigue measures.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100434"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147537836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rotigotine and parkinsonism-hyperpyrexia syndrome","authors":"Shohei Watanabe ,&nbsp;Ayano Hasuike ,&nbsp;Hosho Morishita ,&nbsp;Koji Yagi ,&nbsp;Eiko Fujiwara ,&nbsp;Daisuke Yamanaka ,&nbsp;Shuhei Kasama ,&nbsp;Masataka Igeta ,&nbsp;Takashi Kimura","doi":"10.1016/j.prdoa.2026.100447","DOIUrl":"10.1016/j.prdoa.2026.100447","url":null,"abstract":"<div><h3>Introduction</h3><div>Parkinsonism–hyperpyrexia syndrome (PHS) is a potentially fatal complication of Parkinson’s disease (PD) often triggered by antiparkinsonian medication discontinuation or reduction. Rotigotine, a transdermal dopamine agonist, provides continuous drug delivery and can be administered even when oral administration is difficult. However, the association between rotigotine use and development of PHS remains unclear.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 166 episodes of emergency hospitalization for PD at Hyogo Medical University Hospital (2010–2024). After excluding 19 episodes with insufficient data, 147 were analyzed. Thirty episodes met the diagnostic criteria for PHS (PHS group), and 117 episodes did not (non-PHS group). Clinical characteristics, antiparkinsonian medications, and precipitating events during hospitalization were assessed. A multivariable logistic regression analysis was performed using age, sex, disease duration, and rotigotine administration as covariates.</div></div><div><h3>Results</h3><div>The PHS group had a shorter disease duration, lower modified Hoehn and Yahr stages, and a lower levodopa equivalent dose than the non-PHS group. Poor medication compliance was the most common precipitating factor among PHS cases (n = 11, 36.7%). Rotigotine was administered in five PHS and 41 non-PHS episodes. In the multivariable analysis, age was significantly negatively associated with the development of PHS (odds ratio [OR], 0.894; 95% confidence interval [CI], 0.840–0.952; p = 0.0005). And rotigotine administration showed a tendency to suppress the development of PHS (OR, 0.353; 95% CI, 0.121–1.031; p = 0.0569).</div></div><div><h3>Conclusion</h3><div>Although not statistically significant, rotigotine use tends to be associated with a lower incidence of PHS. Maintaining good medication adherence is critical for preventing PHS, and we consider that rotigotine may be a useful therapeutic option.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100447"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Essential tremor-like phenotype in Fragile X carrier women","authors":"Deborah A Hall ,&nbsp;Danuta Loesch ,&nbsp;Tyler Svymbersky ,&nbsp;Elizabeth Berry-Kravis ,&nbsp;Bichun Ouyang","doi":"10.1016/j.prdoa.2026.100436","DOIUrl":"10.1016/j.prdoa.2026.100436","url":null,"abstract":"<div><h3>Background</h3><div>Tremor is a key feature of the neurodegenerative fragile X-associated tremor ataxia syndrome (FXTAS) and typically affects fragile X gene (<em>FMR1</em>) premutation carriers over the age of 55.</div></div><div><h3>Objective</h3><div>To determine if tremor occurs in <em>FMR1</em> premutation carriers who do not meet criteria for FXTAS.</div></div><div><h3>Methods</h3><div>Data from two cohorts of premutation carriers (n = 97) and controls (n = 22) were analyzed, and included FXTAS rating scale items such as handwriting, spiral drawing, and finger-to-nose maneuver as rated by a movement disorder neurologist who was blinded to gene status. Premutation carriers who met criteria for FXTAS were excluded. Descriptive, univariate and multivariate methods were used to analyze the differences between the groups.</div></div><div><h3>Results</h3><div>FXTAS Rating Scale scores were higher in premutation carriers without FXTAS compared to controls (7 ± 5 vs. 4 ± 3, p = 0.002) and remained significantly higher after correcting for age (p = 0.003). Individual tremor items that were significantly worse included finger-to-nose and spiral drawing.</div></div><div><h3>Conclusions</h3><div>Isolated hand tremor can be seen in <em>FMR1</em> premutation carriers who do not meet criteria for FXTAS. Additional work needs to be done to determine if these carriers are at higher risk of developing FXTAS in the future or if this is a benign condition. When clinicians are evaluating and counseling <em>FMR1</em> premutation carriers with tremor, it should be acknowledged that it is not yet know of the individual will develop FXTAS or whether the tremor will remain isolated.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"14 ","pages":"Article 100436"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147703056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repetitive transcranial magnetic stimulation for freezing of gait in Parkinson's disease: a systematic review and meta-analysis","authors":"Lara Hamzeh Hamzeh,&nbsp;Yahya Kayed AbuJwaid,&nbsp;Sara M.F. Fahmy,&nbsp;Dania AbuHawas,&nbsp;Habiba Tariq Saeed,&nbsp;Daher Heib,&nbsp;Mawatheeq Al-Yafrosi,&nbsp;Ahmed Noureldeen Abbas,&nbsp;Karima El Refaei,&nbsp;Christian Cortes Armijo,&nbsp;Majd A. AbuAlrob","doi":"10.1016/j.prdoa.2026.100465","DOIUrl":"10.1016/j.prdoa.2026.100465","url":null,"abstract":"<div><h3>Background</h3><div>Freezing of gait is among the most disabling motor complications of Parkinson's disease, markedly increasing fall risk and reducing quality of life. Repetitive transcranial magnetic stimulation has emerged as a non-invasive neuromodulation approach; however, evidence regarding its efficacy for freezing of gait remains heterogeneous and inconclusive.</div></div><div><h3>Objectives</h3><div>To evaluate the efficacy and safety of repetitive transcranial magnetic stimulation for freezing of gait and motor outcomes in Parkinson's disease.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (PROSPERO: CRD420261285716). PubMed, Scopus, Cochrane Library, and Web of Science were searched through January 2026 for randomized controlled trials. The primary outcome was freezing of gait severity measured by the Freezing of Gait Questionnaire. Pooled standardized mean differences were calculated using random-effects modeling.</div></div><div><h3>Results</h3><div>Twelve randomized controlled trials comprising 293 participants were included. Repetitive transcranial magnetic stimulation significantly improved freezing of gait severity as measured by the Freezing of Gait Questionnaire (standardized mean difference = −0.97, 95% confidence interval − 1.39 to −0.55; <em>p</em> &lt; 0.001). Significant improvements were also observed in motor function, Timed Up and Go performance, gait speed, step/stride length, turn time, and turn steps, whereas cadence did not differ significantly. No serious adverse events were reported.</div></div><div><h3>Conclusions</h3><div>Repetitive transcranial magnetic stimulation significantly improves freezing of gait and motor performance in Parkinson's disease, representing a safe and promising adjunctive therapy for gait disturbances refractory to conventional treatment. Future large-scale trials with standardized protocols are needed to confirm long-term efficacy.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100465"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13292664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148333283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing receipt of specialty neurologic care for patients with Huntington's disease in Colorado","authors":"Amy C. Ogilvie,&nbsp;Emily Forbes,&nbsp;Chun Chieh Lin,&nbsp;James F. Burke,&nbsp;Hillary D. Lum,&nbsp;Sean M. Reed","doi":"10.1016/j.prdoa.2026.100473","DOIUrl":"10.1016/j.prdoa.2026.100473","url":null,"abstract":"<div><h3>Background</h3><div>Despite recognized importance of specialized neurological care for patients with Huntington's disease (HD), little is known about the number or characteristics of patients who receive this type of care.</div></div><div><h3>Objectives</h3><div>To identify differences between patients receiving care from a movement disorders specialist (MDS) compared to a general neurologist using data from the Colorado All Payers Claims Database between 2019 and 2022.</div></div><div><h3>Methods</h3><div>Logistic regression models were used to compare characteristics of patients who had received care from a MDS compared to a general neurologist in a given year.</div></div><div><h3>Results</h3><div>Approximately half (49.9%) of patients with HD received care from any neurologist and a third (33.8%) received care from a MDS. There were no differences in characteristics between patients who received MDS care compared to general neurologist care.</div></div><div><h3>Conclusions</h3><div>Practice-related characteristics and patient perspectives on care access warrant further study to clarify barriers to specialized neurological care.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100473"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous subcutaneous foscarbidopa/foslevodopa infusion as a therapeutic option in spinocerebellar ataxia type 8 presenting with early-onset parkinsonism","authors":"Francesco Onorati,&nbsp;Lorenzo Malfer,&nbsp;Lauren M. Jackson,&nbsp;Zhiyv Niu,&nbsp;Owen A. Ross,&nbsp;Rodolfo Savica","doi":"10.1016/j.prdoa.2026.100496","DOIUrl":"10.1016/j.prdoa.2026.100496","url":null,"abstract":"<div><div>In response to a case report on a patient with spinocerebellar ataxia type 8, presenting with early-onset parkinsonism and treated with deep brain stimulation, we report an analogous case, who responded optimally to continuous subcutaneous foscarbidopa/foslevodopa infusion.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100496"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13560312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148945739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}